Side Effect Profile: In trials, both treatments had similar types of side effects, with gastrointestinal symptoms (nausea, upset stomach, constipation) being the most common for each
Patients and clinicians are encouraged to monitor updates from the MHRA, EMA, and NICE as the evidence base for retatrutide continues to develop, and to rely on authoritative sources including the MHRA website, NICE guidance, and peer-reviewed trial publications rather than anecdotal reports when making treatment decisions
Yet most available evidence points to CNS as a major target for GLP-1 and the analogs' effects on appetite (24, 25)
Importantly, we looked at data from two different real-world scenarios when patients report side effects: first, when prompted during their regularly scheduled treatment check-ins, and, second, when they reach out unprompted on their own